FDA has approved InnoMed's Nasal-Aire II Petite for continuous positive airway pressure (CPAP) therapy for the treatment of obstructive sleep apnea in children aged older than 7 years or weighing more than 40 lbs.
FDA has approved InnoMed's Nasal-Aire II Petite for continuous positive airway pressure (CPAP) therapy for the treatment of obstructive sleep apnea in children aged older than 7 years or weighing more than 40 lbs. This product is the first to use a nasal prong/nasal cannula/nasal pillow design rather than the traditional over-the-nose mask, a change that is intended to lead to greater patient compliance.
This device was also approved to provide positive pressure-based noninvasive ventilation for pediatric patients in both acute care and home settings.
Major congenital malformations not linked to first trimester tetracycline use
November 22nd 2024A large population-based study found that first-trimester tetracycline exposure does not elevate the risk of major congenital malformations, though specific risks for nervous system and eye anomalies warrant further research.